Page 1,587«..1020..1,5861,5871,5881,589..1,6001,610..»

Biotechnology: navigating a minefield – Youris.com

Posted: April 12, 2017 at 7:44 am

In our fast-moving world, biotech is at the forefront of developments but, by its very nature, it can provoke ethical and moral concerns.

The European Patent Office (EPO) has faced opposition in the past, for instance, over patents relating to processes for re-engineering genes, for use in medical research into cancer treatment. These processes could apply to various animals, including great apes and that became a magnet for criticism from animal rights campaigners.

The number of patent filings for biotechnology increased by 0.3 percent in 2016, to 5,744 making it the tenth largest sector in its field.

Youris.com spoke to Benoit Battistelli, President of the EPO, about the role of patent protection and how it can aid biotechnology innovation and the wider bioeconomy despite the obstacles faced by some.

Benoit Battistelli -Courtesy of EPO

How much of a focus is the bioeconomy for patents and what are some of the key developments? Biosciences play an important role in patent applications at the EPO, given the growing convergence of technologies, which is widely responsible for technical progress in a wide number of sectors. Such inventions are mainly found in industrial biotechnology, for instance, in the development of novel products such as new detergents, functional food or even new eco-friendly material in construction, such as pollution-eating concrete and self-healing concrete.

The area of clean energy production is also very important. For example, when it comes to using biomass as an energy source [editors note: In 2011, a Danish inventor won a European Inventor Award organised by the EPO for developing a system which increases the types of biomass fuels that can be used. Typically, biomass materials have to be dried before they can be used as fuel, but Jens Dall Bentzens furnace design can also burn materials with a moisture content of up to 60 percent. Hes since reported to have attracted interest from Europe and the US, selling the furnace to an American manufacturer, as well as building two others for use in Denmark].

Is the bioeconomy an increasing sector? Biotech is among our top ten technical fields and it has increased. At the end of the patent granting process, its about 50 percent on average that become a patent. Its only 26 or 27 percent in the case of biotech. Why? Because it is a very sensitive issue and we are applying the patentability criteria very rigorously. There are huge European capacities in biotech and we have seen that we must find a good balance between the regulatory constraints and the economic capacities that this sector represents.

The position of the EPO is very clear and simple. There is an EU directive concerning biotech, which we respect and which we have integrated in our own legal framework, the European Patent Convention. Then you have the interpretations of the Directive by the European Court of Justice and we adapt our practice to these judgements.

Overall, how complicated is it to obtain a patent, and is it expensive? I would not say that it is complicated, but it is a difficult process, because we always start from the basis thata patent is an exception to the principle of free trade, free industry, free competition. Globally, for around20 to 25,000 euros, you can obtain a patent as the EPO. For this amount, 5,000 euros are the EPO fees and the rest is the fees of those who helped to draft a patent and then discuss it with the patent office.

So, with a patent, you are giving the holderthe exclusive right of commercially exploiting his invention, for a certain period of time, amaximum 20 years.

This article is part of the communication of theProBIO project, a support action for KBBE projects which identifies research results to facilitate their uptake into the relevant sector.

youris.com provides its content to all media free of charge. We would appreciate if you could acknowledge youris.com as the source of the content.

See the rest here:
Biotechnology: navigating a minefield - Youris.com

Posted in Biotechnology | Comments Off on Biotechnology: navigating a minefield – Youris.com

Technical Roundup On Two Stocks – Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) – Post Analyst

Posted: April 12, 2017 at 7:44 am

Technical Roundup On Two Stocks - Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO)
Post Analyst
Puma Biotechnology, Inc. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 27.36% of shares outstanding. The stock sank -19.31% last month and is up 17.75 this year. Wall ...

and more »

Continued here:
Technical Roundup On Two Stocks - Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) - Post Analyst

Posted in Biotechnology | Comments Off on Technical Roundup On Two Stocks – Puma Biotechnology, Inc. (PBYI), Diamond Offshore Drilling, Inc. (DO) – Post Analyst

Venture capitalists are betting big on regenerative medicine, but it’s … – Quartz

Posted: April 12, 2017 at 7:43 am

Until the myth of the fountain of youth proves true, regenerative medicine is the best hope weve got for fixing failed body parts and, as a result, living longer. Scientists wont be able to bottle forever. They are, however, working on engineering human cells, tissues, and organs that can repair themselves.

Basically, theyre trying to heal body parts using cells or tissue grown from stem cells, and by prompting regeneration with biologically active drugs that would essentially restart parts by forcing new growth, among other approaches. But its still a speculative venture, say Goldman Sachs analysts in an April 4 report on venture capital going into this novel frontier.

Perfecting processes for regenerating body parts is no mean feat, technically speaking. Plus, there are ethical questions to resolve and regulatory hurdles to overcome. In other words, itll take a while before new parts are available.

Nonetheless, investors are interested in the field, and especially in companies working with stem cells. Goldman analysts believe regenerative medicine is attractive because of its vast potential to eventually cure common and rare diseases in almost any tissue or organ, including the heart, liver, and lungs.

So, moneys going to regenerative medicine, at a rate of hundreds of millions of dollars annually. In 2010, the field attracted about $200 million in venture capital and in 2016, that figure had quadrupled. Stem cell technology attracts the vast majority of investment; $700 million of the $800 million dedicated to regenerative medicine in 2016 went to stem cell projects.

But analysts noted that the number of deals hasnt increased accordingly. Between 2010 and 2016 deals remained in a range of 30 to 40 while investment rose pretty steadily. This suggests that a few companies attracted larger investments per deal over time from venture capital firms.

Companies partnered with science giantslike BlueRock Therapeutics, which works with stem cell pioneer and Nobel laureate Shinya Yamanaka of Kyoto Universityget the largest investments and valuations, according to Goldman Sachs.

Analysts also remarked on Unity Biotechnology, which is developing a technique to eliminate senescent cellsor expiring cellsto increase longevity and maintain youthfulness, and has been shown to work in mice. Senescence is like a biological emergency brake cells use to stop dividing and multiplying out of control. But after the brakes been pulled, the senescent cells remain and accumulate, secreting inflammatory molecules that harm neighboring cells and tissues. Selectively removing them could keep people younger, healthier longer, according to the company.

Scientists seek funding from public sources too, of course. At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, for example, researchers are manipulating stem cells to heal and restore the function in hearts, eyes, kidneys and other tissues, according to Charles Murray, the institutes interim director. In an April 9 editorial in the Seattle Times, he writes, This year, we also seek a first-time investment from our state legislature.

Continued here:
Venture capitalists are betting big on regenerative medicine, but it's ... - Quartz

Posted in Cell Medicine | Comments Off on Venture capitalists are betting big on regenerative medicine, but it’s … – Quartz

Two new Series A rounds inject $72M into regenerative medicine and NASH – MedCity News

Posted: April 12, 2017 at 7:43 am

Two of the hottest fields in biopharma got another injection of cash this week, with a combined $72 million in Series A financing.

That includes $32 million raised by Frequency Therapeutics to further its novel regenerative medicine approach, and a separate $40 million round for Cirius Therapeutics take on liver fibrosis and NASH.

Headquartered in Woburn, Massachusetts,Frequency Therapeutics was founded in 2015 with a mission to kickstart one of the bodys natural healing mechanisms. Its$32 million Series A financing round was led by CoBro Ventures, with support from Morningside Ventures, Emigrant Capital, Korean Investment Partnership, Alexandria Real Estate Equities,and others.

Frequency is built around its so-called Progenitor Cell Activation (PCA) platform developed by Robert Langer and Jeffrey Karp from MIT and Harvard Medical School. Progenitor cells are slightly more specialized than stem cells. And while they typically lie dormant after fetal development, they can be activated to regenerate damaged tissues similar to the way stems cells do.

Theyre already in the right place and trained to do the right job, explained Frequencycofounder and CSO Chris Loose, in an email forwarded by a company representative.

While the PCA platform could theoretically be applied to many fields, such as skin disorders, muscle regeneration, and gastrointestinal diseases, the initial R&D focus will bechronic hearing loss. This often occurs with the gradual loss of key cells in the inner ear, called sensory hair cells.

Frequencys small molecule therapy would activate the progenitor cells waiting in the wings, helping to replace the lost cells and loss of function for the remainder of the patients life.

Once a new hair cell is regenerated, we expect it to be long-lasting, Loose explained. The hair cells you are born with are the ones you die with, so a hair cell can survive and function for over 100 years in some people.

Also on Tuesday,Cirius Therapeutics (previously known as Octeta Therapeutics) publicized a $40 million Series A round. The financing was led by Frazier Healthcare Partners and Novo A/S.

The money is destined to fund the companys ongoingEMMINENCE trial, a Phase 2b study of its second-generation insulin sensitizer, MSDC-0602K, for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis.

It speaks to the novel approach Cirius is taking to control the silent epidemic of NASH, which often strikes alongside obesity, metabolic syndrome, and type 2 diabetes.

In a company statement, newly-announced CEO Bob Balteraexplainedthe connection.

A great deal of experimental data, including results from a Phase 2 trial in patients with Type 2 diabetes, has been generated demonstrating that these next-generation insulin sensitizers act in a novel way to positively impact the underlying metabolic parameters that drive NASH,Baltera said.

The challenge for the company is ensuring the safety of its candidate,MSDC-0602K. While promising, existing insulin sensitizers come with an array of problematic side effects and NASH is a high-risk patient population.

On the other hand, there are no disease-modifying therapies on the market, so a little benefit will go a long way.

Echoing others in the field, one of the lead investors noted that a combination approach to NASH will likely work best.

At Frazier, we believe the future of NASH therapies will be a multi-drug approach, with a need for therapies that address the underlying metabolic drivers of disease, as well as resultant fibrosis and inflammation, said Dan Estes of Frzaier Healthcare. We see a distinct opportunity for MSDC-0602K to become a cornerstone therapy in NASH, both as monotherapy but ultimately as part of combination approaches.

Photo: abluecup, Getty Images

Excerpt from:
Two new Series A rounds inject $72M into regenerative medicine and NASH - MedCity News

Posted in Cell Medicine | Comments Off on Two new Series A rounds inject $72M into regenerative medicine and NASH – MedCity News

James Rothman appointed Sterling Professor of Cell Biology – Yale News

Posted: April 12, 2017 at 7:43 am

James E. Rothman, newly appointed as a Sterling Professor of Cell Biology, is one of the world's most distinguished biochemists and cell biologists. For his work on how molecular messages are transmitted inside and outside of human cells, he was awarded a Nobel Prize in 2013.

A Sterling Professorship is one of the universitys highest faculty honors.

Rothman helped reveal the mechanism that allows cellular compartments called vesicles to transmit information both in the interior of the cell and to the surrounding environment. The fusion of vesicles and cellular membranes, a process called exocytosis, is basic to life and occurs in organisms as diverse as yeast and humans. Exocytosis underlies physiological functions ranging from the secretion of insulin to the regulation of the brain neurotransmitters responsible for movement, perception, memory, and mood.

Rothmans current research concerns the biophysics of membrane fusion and its regulation in exocytosis; the dynamics of the Golgi apparatus at super-resolution; and the use of bio-inspired design in nanotechnology.

After graduating from Yale College with a degree in physics, Rothman earned a Ph.D. in biological chemistry from Harvard Medical School. He conducted postdoctoral research at the Massachusetts Institute of Technology before moving to the Stanford School of Medicine as an assistant professor. He continued his research at Princeton University, where he became the founding chair of the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center and vice chair of the Sloan-Kettering Institute. Prior to coming to Yale in 2008, Rothman served on the faculty of Columbia Universitys College of Physicians and Surgeons, where he was a professor in the Department of Physiology and Biophysics, the Clyde and Helen Wu Professor of Chemical Biology, and director of the Columbia Genome Center.

Rothman serves as chair of the Yale School of Medicines Department of Cell Biology and as director of the Nanobiology Institute on Yales West Campus.

He has received numerous awards and honors in recognition of his work on vesicle trafficking and membrane fusion, including the King Faisal International Prize for Science, the Gairdner Foundation International Award, the Lounsbery Award of the National Academy of Sciences, the Heineken Foundation Prize of the Netherlands Academy of Sciences, the Louisa Gross Horwitz Prize of Columbia University, the Lasker Basic Science Award, the Kavli Prize in Neuroscience, the Massry Prize, and the E.B. Wilson Medal. He is a member of the National Academy of Sciences and its Institute of Medicine, and is a fellow of the American Academy of Arts and Sciences.

Go here to see the original:
James Rothman appointed Sterling Professor of Cell Biology - Yale News

Posted in Cell Medicine | Comments Off on James Rothman appointed Sterling Professor of Cell Biology – Yale News

Taking Cell Therapy one Step Further with this Boost Reagent – Labiotech.eu (blog)

Posted: April 12, 2017 at 7:43 am

Cell therapy is revolutionizing medicine, heres how the latest technology can help overcome the major challenges stopping it from taking over the market.

Offering unprecedented possibilities to treat some of the most challenging diseases, cell therapy is stealing the show in the biotech space. Strimvelis, the first hematopoietic stem cell (HSC) gene therapy is already treating rare genetic diseases. In less than a year, CAR-T therapy is expected to hit the market and revolutionize the treatment of cancer. And in the not-so-far future, cell therapy could even eradicate HIV or put an end to diabetes, which is reaching epidemic proportions in Western countries.

The first cell therapies have already been on the market for a few years, and analysts are confident that the numbers will quickly grow over the years. The stem cell therapy market alone is expected to hit 57Bn ($61Bn) by 2022, and the upcoming CAR-T technology will reach an impressive 8Bn ($8.5Bn) in the next decade.

Although the potential is definitely there, researchers are still looking for ways of making these therapies cheaper, safer and more effective. Currently, not all patients are suited to receive cell therapy due to scientific or economic challenges. The advent of allogeneic therapies is addressing the financial obstacles, but what about efficiency?

One of the key elements to building a successful cell therapy are viral vectors, which are used to deliver the necessary DNA sequences to engineer the cells. Lentiviral vectors are a common choice because they have a rather larger capacity and enable long-lasting genetic expression.

They are specially researched for ex-vivo treatment of hematopoietic stem cells and primary T-cells. The percentage of cells that can be reached, however, often remains low, and the number of gene copy numbers per cell can be extremely variable.

Finding a solution to this challenge is unfortunately not as simple as increasing the virus load. Cells that carry a surplus of copies integrated into their DNA are more prone to mutations that affect their survival and put the safety of the patient in danger. This is an essential factor taken into account during the regulatory phase to determine whether a therapy can make it to the market or not.

How can we then improve the efficacy of transduction without affecting the health of the cells and the safety of the therapy? In the lab, researchers often use enhancers such as polybrene, a polymer that can increase the efficacy of transduction of viral DNA. However, this substance is not applicable in a clinical context because of its heightened cell toxicity.

To overcome these challenges, scientists at SIRION Biotech got down to work and screened for compounds that could improve the fusion of the viral and cell membranes. The result was a technology with the potential to solve a major problem in the development of cell therapies, with DNA delivery reaching an impressive 80% of hematopoietic stem cells while keeping the copy numbers down to the ideal value of 3 to 5 per cell.

This technology, called LentiBOOST, works its magic simply by adding a non-toxic polymer to the mixture during transduction. It has already been accepted as an element of clinical trials from phase I to phase III and its possibilities seem unlimited. One of SIRIONs partners, the Heinrich Pette Institute in Hamburg, is studying the potential of LentiBOOST to improve transduction in a therapy intended to actively remove HIV from infected blood cells and induce long-lasting resistance against the virus.

With applications ranging from cancer to infectious disease, cell therapy is definitely going to change medicine. Technology like LentiBOOST is helping these amazing developments materialize with a boost to both their efficacy and safety.

You can find more information on LentiBOOST at SIRION Biotechs website!

Images from Montri Thipsorn, vchal /Shutterstock; SIRION Biotech

Here is the original post:
Taking Cell Therapy one Step Further with this Boost Reagent - Labiotech.eu (blog)

Posted in Cell Therapy | Comments Off on Taking Cell Therapy one Step Further with this Boost Reagent – Labiotech.eu (blog)

Fresh fruit may prevent diabetes and related complications – Medical News Today

Posted: April 12, 2017 at 7:42 am

Most of us know that eating fresh fruit and vegetables is good for our health. However, people diagnosed with diabetes may avoid fruit due to its high sugar content. New research investigates the health benefits of fresh fruit consumption among people with diabetes.

Diabetes affects more than 420 million people worldwide and more than 29 million people in the United States alone.

According to the World Health Organization (WHO), diabetes caused more than 1.5 million deaths in 2012. In the U.S., diabetes is a leading cause of death, accounting for almost 80,000 yearly deaths, according to the latest statistics from the Centers for Disease Control and Prevention (CDC).

Fresh fruit and vegetables are healthful for most of us, but people with diabetes may abstain from eating fresh fruit because of its high sugar content.

This is why a team of researchers - led by Huaidong Du of the University of Oxford in the United Kingdom - decided to investigate the health effects of consuming fresh fruit in patients both with and without diabetes.

The authors were also motivated by the fact that, to their knowledge, no studies have so far investigated the long-term effects of fresh fruit consumption on the rate of diabetes or on the risk of diabetes-induced cardiovascular events.

The research was published in the journal PLOS Medicine.

The researchers examined the effects of fruit consumption on almost 500,000 people enrolled in the China Kadoorie Biobank national study. Participants were aged between 30 and 79 and lived in 10 different areas across China.

The participants were clinically followed for approximately 7 years.

During this follow-up period, 9,504 cases of diabetes were identified in participants who did not have diabetes at the beginning of the study.

Using Cox regression models, researchers analyzed the correlations with consumption of fresh fruit while also adjusting for age, sex, location, socioeconomic status, body mass index (BMI), and family history of diabetes.

In total, 18.8 percent of the participants said that they consumed fresh fruit every day, and 6.4 percent said that they never or rarely consumed them. Those who had been previously diagnosed with diabetes were three times as likely to not consume fruit than those without diabetes or with screen-detected diabetes.

The team found that people who did not have diabetes at the beginning of the study and consumed fresh fruit in high amounts had a significantly lower risk of diabetes. Additionally, those who had diabetes at the beginning of the study and consumed high amounts of fruit had a significantly lower risk of dying from any cause, as well as a lower risk of developing cardiovascular complications.

More specifically, in comparison with the other study participants, those who consumed fresh fruit daily had a 12 percent lower relative risk of developing diabetes.

Study participants who had diabetes at baseline but consumed fresh fruit more than three times per week had a 17 percent lower risk of all-cause mortality and up to a 28 percent lower risk of developing both major and minor cardiovascular complications.

"Major" cardiovascular complications refer to events that affect large blood vessels (ischemic heart disease and stroke, for instance), while "minor" refers to those affecting small blood vessels (such as kidney diseases, eye disease, and neuropathy).

In absolute terms, this means that daily fruit-consumers had a 0.2 percent decrease in their absolute risk of developing diabetes over a 5-year period, and people diagnosed with diabetes had a 1.9 percent absolute reduction in the risk of mortality from all causes.

Du and team explain the significance of these findings:

"These findings suggest that a higher intake of fresh fruit is potentially beneficial for primary and secondary prevention of diabetes. For individuals who have already developed diabetes, restricted consumption of fresh fruit, which is common in many parts of the world [...] should not be encouraged."

The study was purely observational, so no conclusions were drawn regarding causality.

Learn how legumes may lower the risk of type 2 diabetes.

Read this article:
Fresh fruit may prevent diabetes and related complications - Medical News Today

Posted in Diabetes | Comments Off on Fresh fruit may prevent diabetes and related complications – Medical News Today

Michigan Medicine ranks in 90th percentile for diabetes performance – University of Michigan Health System News (press release)

Posted: April 12, 2017 at 7:42 am

ANN ARBOR, Mich. Michigan Medicine has ranked in the 90th percentile of the AMGA Foundations Diabetes: Together 2 Goal campaign for its diabetes performance related to lipid management.

The campaign, launched in March 2016, has a goal to improve care for 1 million people with type 2 diabetes by 2019. AMGA Foundation hopes to achieve this goal by leveraging the coordinated delivery systems of 150 participating AMGA members as well as national partners and collaborators.

Each quarter, nearly two-thirds of medical groups and health systems that participate in the campaign report diabetes prevalence and control rates in their patient populations. AMGA Foundation then recognizes participants who are high performers in different areas of diabetes care, such as A1c control, blood pressure control, lipid management and medical attention to nephropathy, in an effort to continue improving diabetes care across the nation.

Based on self-reported data for Q3 2016, Michigan Medicine ranked in the 90th percentile for its lipid management performance for diabetes patients.

We are pleased to be recognized for excellence in patient care, says Jennifer Wyckoff, M.D., assistant professor of endocrinology at Michigan Medicines Division of Metabolism, Endocrinology and Diabetes. We have taken many steps over the past 15 years to ensure top quality care for patients with diabetes, including quality metric dashboards and panel managers for our primary care clinics, a comprehensive diabetes education program and working with patient advocates.

AMGA congratulates Michigan Medicine for their commitment to care for people with type 2 diabetes, says Jerry Penso, M.D., M.B.A., president of AMGA Foundation and chief medical and quality officer of AMGA. Lipid management is an incredibly vital component of type 2 diabetes management, as heart disease and stroke are the top causes of death and disability among this population.

About Michigan MedicineAt Michigan Medicine, we create the future of healthcare through the discovery of new knowledge for the benefit of patients and society; educate the next generation of physicians, health professionals and scientists; and serve the health needs of our citizens. We pursue excellence every day in our three hospitals, 40 outpatient locations and home care operations that handle more than 2.1 million outpatient visits a year.

About AMGA Foundation AMGA Foundation is AMGAs philanthropic arm that enables medical groups and other organized systems of care to consistently improve health and health care. AMGA Foundation serves as a catalyst, connector and collaborator for translating the evidence of what works best in improving health and health care in everyday practice.Learn more atamga.org/foundation.

About AMGA AMGAis a trade association leading the transformation of health care in America. Representing multispecialty medical groups and integrated systems of care, we advocate, educate, innovate and empower our members to deliver the next level of high performance health. AMGA is the national voice promoting awareness of medical groups recognized excellence in the delivery of coordinated, high-quality, cost-effective care. More than 175,000 physicians practice in our member organizations, delivering care to one in three Americans. Learn more atamga.org.

Read more:
Michigan Medicine ranks in 90th percentile for diabetes performance - University of Michigan Health System News (press release)

Posted in Diabetes | Comments Off on Michigan Medicine ranks in 90th percentile for diabetes performance – University of Michigan Health System News (press release)

Merck, Amazon challenge developers to build Alexa apps for diabetes – MobiHealthNews

Posted: April 12, 2017 at 7:42 am

Amazon Web Services and Merck announced a developer competition on Monday to that plans to harness artificial intelligence for diabetics.

Dubbed the Alexa Diabetes Challenge, and powered by Luminary Labs, the contest aims to incent upstarts and individual developers to create apps that harness Amazons Alexa voice-enabled technologies particularly for patients recently diagnosed with Type 2 diabetes.

Early adopters such as Penn Medicine and Commonwealth Care Alliance are already running proofs-of-concept or pilot programs with Amazon Alexa being the centerpiece of improving patient experience.

Whats more, a new Healthcare IT News andHIMSS Analytics HIT Market Indicator reportfound that half of hospitals intend to adopt some fashion of AI in five years and more than a third plan to do so within two years.

The Amazon and Merck contest enables innovators to use not only Alexa but also Amazon Web Services cloud infrastructure.

Five entrants will be chosen in the first round. Those winners will collect $25,000 and 100,000 AWS credits apiece and move into the Virtual Accelerator to access mentors as they work to transform the initial concepts into real solutions, the companies said.

The accelerator work will culminate with the finalists presenting their apps to judges in a pop-up AWS loft in New York City, after which the winner will be awarded $125,000.

At the end of the Virtual Accelerator, finalists will present their solutions in-person to the judges at Demo Day at the AWS Pop-up loft in NYC. Submissions take place atalexadiabeteschallenge.comand close on May 22, 2017.

Excerpt from:
Merck, Amazon challenge developers to build Alexa apps for diabetes - MobiHealthNews

Posted in Diabetes | Comments Off on Merck, Amazon challenge developers to build Alexa apps for diabetes – MobiHealthNews

Teen works to save summer camp for kids with diabetes – WBIR-TV

Posted: April 12, 2017 at 7:42 am

April 11, 2017: A 16-year-old with Type 1 diabetes is trying to save a summer camp that means so much to her.

Mary Scott, WBIR 6:56 PM. EDT April 11, 2017

Natalie Miller (Photo: WBIR)

Natalie Miller's Type 1 diabetes requires constant care: five blood sugar tests a day, an insulin pump, counting carbohydrates and the list goes on.

While the Powell High School junior has learned to deal with the pain and management of the medical treatments, she remembers when diabetes made her feel like an outcast.

"It definitely took a toll on my self-confidence for a while. I always feel weird, even now, when my pump will go off in class and every one will turn around and look at me," explained Miller, 16.

Camp Cure is a place where she always feels accepted. Every summer, East Tennessee Children's Hospital put on the week-long day camp exclusively for kids dealing with diabetes.

Even after Miller aged out of the camp, she returned as a volunteer counselor.

"For me, it's where I can go and be with people who understand what it's like to get up at three in the morning with low blood sugar. Or understand what it's like to be irritable because you're blood sugar is high," Miller said.

This year, Children's Hospital said it made the decision to close Camp Cure after four months of consideration.

"When we were really examining it, we did not have the finances to support it this year," said Hella Ewing, Children's Hospital VP of Patient Care Services and Chief Nursing Officer.

Camp Cure costs the hospital about $30,000 every year and is the hospital's only summer camp that does not have a financial endowment to cover costs.

Children's two other camps for children with disabilities and medical disorders, Donald M. Gally Summer Camp and Camp Eagle's Nest, have sustainable philanthropic support.

"We thought we would just take a step back, re-energize the camp, see what potential support we might be able to gain from the community and hope we can do it again next year," Ewing said.

Natalie Miller turned her disappointment from the news into action. She wrote a plea to the community to help bring back the camp next year and shared it on social media.

Read Natalie Miller's full letter below:

Let me give you a bit of background information, so you can see why this summer camp is worth the donations. My name is Natalie Miller, I'm sixteen and I've been Type 1 Diabetic for thirteen years this coming December. I was diagnosed at the age of 4, and I attended Camp Cure from the time I was five until age 12 (because that's the age limit for campers! Of course, you can become a junior staff member once you turn 13). Camp Cure was one of the only places where I felt like I fit in. The thing wasand still isthat no one understood me unless they had diabetes as well, which in Powell, is seldom and far between. Everyone understood me there, and knew the pain of having to poke my finger 4-5 times a day, take shots every time I ate and having to count carbs and measure out my food. They understand what it's like to wake up with a low blood sugar and having to muster up the energy to get up and check your blood glucose, or it being a high BG with uncontrolled thirst, urination and headaches. To say that Camp Cure was a big impact on me is an understatement; they took part in molding me into who I am today.

With that being said, we staff members always want to create a good environment for these children and to have fun and show that no disease would slow us down! These kids look up to us, and think "Wow! You can be a teenager with diabetes!" (Yes, they really say that!! Also, our staff are mainly diabetics, trained professionals... we have a team of nurses!) and they look up to us as role models, and trust that we will take great care of them and have lots of fun with them as well. At Camp Cure, we see a lot of firsts: A first finger stick, or a first insulin shot or changing a pump site, and we make a big deal about it as well, as it's such a milestone! Needles and hospital rooms and doctors are intimidating, even for me, and especially for these kids. It's such an honor to be able to witness their face once they realized that they've done something so significant on their own. This camp is so important to me, and lots of other people and kids. Don't let this year be any different from the last. We want to see new smiling faces, and we want to make an impact on these camper's lives. I know how much of a difference they made for me, and I want all of the T1D kids to know that they aren't alone in what they're going through, and we always welcome them with open arms.

Be sure to contact East Tennessee Children's Hospital for more information on how you can get involved with Camp Cure, and how you can chip in to help. Thank you!"

2017 WBIR.COM

The rest is here:
Teen works to save summer camp for kids with diabetes - WBIR-TV

Posted in Diabetes | Comments Off on Teen works to save summer camp for kids with diabetes – WBIR-TV

Page 1,587«..1020..1,5861,5871,5881,589..1,6001,610..»